Editorial Material
Hematology
David M. Ross
Summary: Krishnan et al. present a single-cell transcriptomic atlas of chronic myeloid leukemia (CML) at diagnosis in the latest issue of Blood. They identify cellular features at diagnosis that can predict the response to tyrosine kinase inhibitor (TKI) therapy by comparing different groups with varying treatment outcomes.
Editorial Material
Hematology
Kaosheng Lv, Wei Tong
Summary: In this study, Zhao et al found that downregulation of MS4A3 contributes to the persistence, progression, and drug resistance of chronic myeloid leukemia (CML) to the BCR-ABL inhibitor imatinib. Thus, enhancing MS4A3 levels could be a potential therapeutic strategy in treating CML.
Editorial Material
Hematology
Aziz Nazha
Summary: The study suggests that early BCR-ABL1 kinetics can be used to predict the likelihood of treatment-free remission in patients with chronic myeloid leukemia receiving TKIs.
Editorial Material
Hematology
Charles A. Schiffer
Summary: The outlook for patients with chronic phase chronic myelogenous leukemia (CML) has significantly improved in recent years with the development of oral tyrosine kinase inhibitors (TKIs). A study comparing asciminib and bosutinib in chronic phase CML patients previously treated with >= 2 TKIs may offer a better management option for this patient population.
Article
Hematology
David T. Yeung, Naranie Shanmuganathan, Timothy P. Hughes
Summary: Asciminib, a first-in-class allosteric inhibitor of BCR::ABL1 kinase activity, is approved for treating chronic-phase chronic myeloid leukemia patients who failed 2 lines of therapy or have the T315I mutation. It shows high specificity and potency against BCR::ABL1, activity against most kinase domain mutations, and potential for combination therapy. Clinicians now have expanded third-line options, choosing between asciminib and ponatinib in most cases.
Article
Pharmacology & Pharmacy
An-Ni Zhong, Yi Yin, Bing-Jie Tang, Lei Chen, Hong-Wei Shen, Zhi-Ping Tan, Wen-Qun Li, Qun He, Bao Sun, Yan Zhu, Jie Xiao, Zhi-Ping Jiang, Ping Xu
Summary: The study revealed that hsa_circ_0058493 was significantly overexpressed in PBMCs of CML patients and associated with poor clinical efficacy of imatinib. Silencing this circRNA significantly inhibited the development of imatinib-resistant CML cells, suggesting its potential as a therapeutic target.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Cell Biology
Alena Malyukova, Dorina Ujvari, Elham Yektaei-Karin, Ana Zovko, Harsha S. Madapura, Marton Keszei, Noemi Nagy, Kourosh Lotfi, Niclas Bjorn, Jonas Wallvik, Minori Tamai, Thao T. T. Nguyen, Koshi Akahane, Takeshi Inukai, Leif Stenke, Daniel Salamon
Summary: Combining TKI treatment with a small-molecule MCL1 inhibitor demonstrated strong synergistic antiviability and proapoptotic effects on CML cells and stem/progenitor cells from untreated CML patients, suggesting that dual targeting of MCL1 and BCR-ABL1 activity may efficiently eradicate residual CML cells without affecting normal hematopoietic stem/progenitors.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Frederic Millot, Meinolf Suttorp, Stephanie Ragot, Guy Leverger, Jean-Hugues Dalle, Caroline Thomas, Nathalie Cheikh, Brigitte Nelken, Marilyne Poiree, Genevieve Plat, Birgitta Versluys, Birgitte Lausen, Marina Borisevich
Summary: The study evaluated the rate of children with childhood chronic myeloid leukemia who remained in molecular response after discontinuing imatinib following sustained deep molecular response (DMR). The findings showed fluctuating molecular free remission rates at different time points post-discontinuation, with no significant influencing factors identified.
Article
Oncology
Jan Zuna, Lenka Hovorkova, Justina Krotka, Amelie Koehrmann, Michela Bardini, Lucie Winkowska, Eva Fronkova, Julia Alten, Rolf Koehler, Cornelia Eckert, Lisa Brizzolara, Marie Trkova, Jan Stuchly, Martin Zimmermann, Paola De Lorenzo, Maria Grazia Valsecchi, Valentino Conter, Jan Stary, Martin Schrappe, Andrea Biondi, Jan Trka, Marketa Zaliova, Giovanni Cazzaniga, Gunnar Cario
Summary: In this retrospective analysis, the prognostic relevance of minimal residual disease (MRD) and other features in BCR::ABL1-positive ALL were investigated. The study found that BCR::ABL1-positive ALL can be divided into typical ALL and CML-like subtype. The overall prognosis of typical ALL and CML-like patients was similar, but there were differences in relapse rates and mortality. MRD had a significant prognostic role in typical ALL, while it was not significant in CML-like patients. The study suggests that early distinguishing between typical BCR::ABL1-positive ALL and CML-like patients is important for optimal treatment approaches.
Article
Oncology
Angela McLigeyo, Jamilla Rajab, Peter Oyiro, Mohammed Ezzi, Yatich Bett, Matilda Ong'ondi, Andrew Odhiambo, Sitna Mwanzi, Nicholas Othieno-Abinya
Summary: This study analyzed the baseline characteristics and factors associated with cytopenia in Chronic Myeloid Leukemia patients treated with imatinib. The results showed no significant differences in gender, age, marital status, occupation, and education level between patients with and without cytopenia. Multivariable analysis revealed that baseline anemia, neutropenia, thrombocytopenia, and thrombocytosis increased the odds of developing cytopenia.
Article
Medicine, Research & Experimental
Mansi Shah, Harish Kumar, Shaowei Qiu, Hui Li, Mason Harris, Jianbo He, Ajay Abraham, David K. Crossman, Andrew Paterson, Robert S. Welner, Ravi Bhatia
Summary: In chronic myeloid leukemia (CML), LT-HSCs expressing low c-KIT levels are primitive, quiescent, and drug-resistant leukemia-initiating cells, representing a critical target for eliminating disease persistence.
Article
Biotechnology & Applied Microbiology
Xunxun Zhu, Jingru Zhang, Yanping Sun, Yan Wang, Qian Liu, Peng Li, Shuang Yu, Na Liu, Jingjing Ye, Daoxin Ma, Chunyan Ji
Summary: miR-23a acts as a tumor suppressor in chronic myeloid leukemia (CML) by downregulating CRYAB expression to control the sensitivity of CML cells to imatinib.
Article
Cell Biology
Di Pan, Wanwan Yang, Yao Zeng, Wenjun Li, Kaizhen Wang, Li Zhao, Jia Li, Yuting Ye, Qinglong Guo
Summary: In this study, AKR1C3 was found to be highly expressed in CML cells under the bone marrow microenvironment. AKR1C3 decreased the activity of Imatinib in K562 and KU812 cells, while inhibition of AKR1C3 enhanced Imatinib sensitivity in vitro. The combination use of AKR1C3 inhibitor Indomethacin effectively prolonged mice survival in the murine model, suggesting AKR1C3 as a promising target to enhance Imatinib treatment in CML. Additionally, miR-379-5p was identified to suppress AKR1C3, providing a potential regulatory axis for overcoming Imatinib resistance in CML.
CELLULAR SIGNALLING
(2021)
Article
Hematology
Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stephane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frederic Millot, Briana Patterson, Jill Samis, Paola Aimone, Alex Allepuz, Ksenia Titorenko, Darintr Sosothikul
Summary: The open-label study on pediatric patients with CML showed sustained efficacy of nilotinib in both newly diagnosed and resistant/intolerant patients. However, patients in both cohorts exhibited attenuated growth rates during treatment. The most common adverse events were increased blood bilirubin, headache, fever, and increased alanine aminotransferase levels, with the safety profile of nilotinib being consistent with previous reports.
Article
Oncology
Mario Tiribelli, Roberto Latagliata, Massimo Breccia, Isabella Capodanno, Maria Cristina Miggiano, Francesco Cavazzini, Cristina Bucelli, Immacolata Attolico, Sabrina Leonetti Crescenzi, Sabina Russo, Mario Annunziata, Federica Sora, Massimiliano Bonifacio, Olga Mulas, Giuseppina Loglisci, Alessandro Maggi, Gianni Binotto, Elena Crisa, Anna Rita Scortechini, Anna Paola Leporace, Rosaria Sancetta, Pamela Murgano, Elisabetta Abruzzese, Fabio Stagno, Davide Rapezzi, Debora Luzi, Iolanda Vincelli, Monica Bocchia, Carmen Fava, Alessandra Malato, Monica Crugnola, Michele Pizzuti, Francesca Lunghi, Sara Galimberti, Matteo Dalmazzo, Renato Fanin, Emilia Scalzulli, Robin Foa, Alessandra Iurlo, Giuseppe Saglio, Giorgina Specchia
Summary: This study analyzed the use of frontline TKI therapy in Italian patients with CP-CML and found that 55% of patients chose imatinib as their first-line treatment, while second-generation TKIs were predominantly used in younger patients and those without comorbidities.
Article
Biochemical Research Methods
Inigo Apaolaza, Edurne San Jose-Eneriz, Luis V. Valcarcel, Xabier Agirre, Felipe Prosper, Francisco J. Planes
Summary: Synthetic lethality (SL) is a type of genetic interaction that results in cell death when the function of two genes is simultaneously lost. In cancer metabolism, SL can be used to predict genetic vulnerabilities and nutrient dependencies. Integrating both genetic and environmental factors, a computational approach is proposed to identify new metabolic synthetic lethal interactions and reveal potential vulnerabilities in different malignancies.
PLOS COMPUTATIONAL BIOLOGY
(2022)
Article
Biology
Jianhao Peng, Guillermo Serrano, Ian M. Traniello, Maria E. Calleja-Cervantes, Ullas V. Chembazhi, Sushant Bangru, Teresa Ezponda, Juan Roberto Rodriguez-Madoz, Auinash Kalsotra, Felipe Prosper, Idoia Ochoa, Mikel Hernaez
Summary: Single-cell RNA-Sequencing is a powerful tool for studying complex regulatory interactions between diverse cell phenotypes. However, current methods are limited in their ability to uncover complex regulatory relationships across related cell types. The presented framework, SimiC, overcomes this limitation by inferring distinct regulatory dynamics per phenotype. SimiC has shown to uncover key regulatory patterns missed by previous methods, with implications for systems biology.
COMMUNICATIONS BIOLOGY
(2022)
Article
Engineering, Biomedical
Uzuri Urtaza, Olatz Guaresti, Izar Gorronogoitia, Ana Zubiarrain-Laserna, Emma Muinos-Lopez, Froilan Granero-Molto, Jm Lamo de Espinosa, Tania Lopez-Martinez, Manuel Mazo, Felipe Prosper, Ane Miren Zaldua, Jon Anakabe
Summary: This study identifies several material-scaffold geometry combinations with potential for excellent cell viability and enhanced chondrogenic properties, making them suitable for cartilage tissue engineering applications.
BIOMEDICAL MATERIALS
(2022)
Article
Oncology
Marian Gimeno, Edurne San Jose-Eneriz, Angel Rubio, Leire Garate, Estibaliz Miranda, Carlos Castilla, Xabier Agirre, Felipe Prosper, Fernando Carazo
Summary: This study demonstrates that incorporating the HUb effect in Genetic Essentiality (HUGE) significantly improves the prediction accuracy of lethal dependencies (LEDs) between genes, and identifies previously unrecognized LEDs. The approach is effective in various tumor types and provides an interactive tool for visualizing the graphs of lethal dependencies.
Article
Agriculture, Dairy & Animal Science
Marta Moya-Jodar, Giulia Coppiello, Juan Roberto Rodriguez-Madoz, Gloria Abizanda, Paula Barlabe, Amaia Vilas-Zornoza, Asier Ullate-Agote, Chiara Luongo, Ernesto Rodriguez-Tobon, Sergio Navarro-Serna, Evelyne Paris-Oller, Maria Oficialdegui, Xonia Carvajal-Vergara, Laura Ordovas, Felipe Prosper, Francisco Alberto Garcia-Vazquez, Xabier L. Aranguren
Summary: The generation of organs using pluripotent stem cells combined with genetically engineered pig embryos through blastocyst complementation could provide a solution to the worldwide shortage of transplantable organs. In this study, a protocol to create vascular-disabled pig embryos using the CRISPR/Cas9 system was optimized, which could contribute to the generation of rejection-free humanized organs in pigs.
Article
Biochemistry & Molecular Biology
Imelda Ontoria-Oviedo, Elena Amaro-Prellezo, Delia Castellano, Elena Venegas-Venegas, Fernando Gonzalez-Santos, Amparo Ruiz-Sauri, Beatriz Pelacho, Felipe Prosper, Maria Dolores Perez del Caz, Pilar Sepulveda
Summary: Impaired wound healing in patients with type 2 diabetes is characterized by chronic inflammation. Specialized pro-resolving lipid mediators (SPMs) are bioactive molecules that regulate inflammation. This study found that LIPINOVA(R), a nutritional supplement rich in SPMs and EPA, promotes wound healing by reducing inflammation and inducing angiogenesis and macrophage polarization.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Maria Victoria Mateos, Felipe Prosper, Jesus Martin Sanchez, Enrique M. Ocio, Albert Oriol, Cristina Motllo, Jean-Marie Michot, Isidro Jarque, Rebeca Iglesias, Maria Sole, Sara Martinez, Carmen Kahatt, Salvador Fudio, Gema Corral, Ali Zeaiter, Lola Montilla, Vincent Ribrag
Summary: The triple combination of plitidepsin, BTZ, and DXM showed moderate activity and acceptable safety in adult patients with relapsed/refractory multiple myeloma.
Review
Oncology
Sofia Huerga-Dominguez, Sara Villar, Felipe Prosper, Ana Alfonso-Pierola
Summary: Acute myeloid leukemia, the most common type of acute leukemia in adults, is associated with poor outcomes, especially in older patients. The combination of new targeted therapies with standard chemotherapy has shown better outcomes for fit patients, while different targeted therapies have provided better overall survival rates for unfit patients with limited toxicity. New immunotherapies or targeted therapies bring new hope for refractory and relapsed acute myeloid leukemia. However, further research and development of combinations of different targeted therapies and maintenance strategies guided by measurable residual disease are needed to improve overall survival rates, especially for relapsed or refractory patients.
Article
Biochemistry & Molecular Biology
Laura Pilar Aguado-Alvaro, Nerea Garitano, Gloria Abizanda, Eduardo Larequi, Felipe Prosper, Beatriz Pelacho
Summary: This study compares the efficiency and specificity of three commonly used fibroblast reporter transgenic mouse models for studying cardiac fibrosis. The results suggest that the PDGFRa-creERT2 mouse strain is the optimal model for CF tracking, while the Col1a1-CreERT2 mouse strain is not suitable. The PostnMCM line is the most reliable model for future cardiovascular disease studies, with specific fluorescent reporter expression in activated CF but not in ECs.
Article
Hematology
Antonio Sacco, Vanessa Desantis, Jon Celay, Viviana Giustini, Fabio Rigali, Francesco D. Savino, Michele Cea, Debora Soncini, Antonia Cagnetta, Antonio G. Solimando, Deborah D'Aliberti, Silvia Spinelli, Daniele Ramazzotti, Camillo Almici, Katia Todoerti, Antonino Neri, Antonella Anastasia, Alessandra Tucci, Marina Motta, Marco Chiarini, Yawara Kawano, Jose A. Martinez-Climent, Rocco Piazza, Aldo M. Roccaro
Summary: Recent investigations have shown that Waldenstrom macroglobulinemia (WM) exhibits an increased number of regulatory T cells (Tregs), and Tregs derived from patients with WM have a peculiar mRNA signature and functional phenotype. WM cells trigger significantly higher induction, expansion, and proliferation of Tregs compared to normal cells, especially in the context of CXCR4(C1013G)-mutated WM cells. CD40/CD40-ligand interaction is identified as an important axis supporting the interaction between WM cells and Tregs.
Article
Biochemistry & Molecular Biology
Elisa Felix-Soriano, Neira Sainz, Marta Fernandez-Galilea, Eva Gil-Iturbe, Jon Celay, Jose A. Martinez-Climent, Maria J. Moreno-Aliaga
Summary: This study aimed to investigate the potential beneficial effects of chronic docosahexaenoic acid (DHA) supplementation on restoring subcutaneous white adipose tissue (scWAT) plasticity in obese aged female mice. The results showed that the DHA-enriched diet reduced adipocyte size and reversed the upregulation of lipogenic genes induced by the high fat diet (HFD). DHA supplementation restored the increase of proinflammatory genes, switched scWAT macrophages profile to a healthier phenotype, and induced beige adipocyte markers in obese aged mice.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY
(2023)
Review
Oncology
Ane Amundarain, Fernando Pastor, Felipe Prosper, Xabier Agirre
Summary: Multiple Myeloma (MM) remains an incurable disease due to high relapse rates and fast development of drug resistances. The introduction of monoclonal antibodies (mAb) has caused a paradigm shift in MM treatment, paving the way for targeted approaches with increased efficacy and reduced toxicities. Nevertheless, antibody-based therapies face several difficulties such as high immunogenicity, high production costs and limited conjugation capacity, which we believe could be overcome by the introduction of nucleic acid aptamers. Similar to antibodies, aptamers can bind to their targets with great affinity and specificity. However, their chemical nature reduces their immunogenicity and production costs, while it enables their conjugation to a wide variety of cargoes for their use as delivery agents. In this review, we summarize several aptamers that have been tested against MM specific targets with promising results, establishing the rationale for the further development of aptamer-based strategies against MM. In this direction, we believe that the study of novel plasma cell surface markers, the development of intracellular aptamers and further research on aptamers as building blocks for complex nanomedicines will lead to the generation of next-generation targeted approaches that will undoubtedly contribute to improve the management and life quality of MM patients.
Article
Biochemistry & Molecular Biology
Federica Grilli, Ennio Albanesi, Beatriz Pelacho, Felipe Prosper, Paolo Decuzzi, Daniele Di Mascolo
Summary: Depositing stem cells at the injury site is a clinically relevant strategy for tissue repair and angiogenesis, but insufficient cell engraftment and survival requires the development of new scaffolds. In this study, a microstructured poly(lactic-co-glycolic acid) (PLGA) fabric was investigated as a promising biodegradable scaffold for adipose-derived stem cell (ADSC) tissue integration. The results showed that ADSCs reassembled into spheroidal-like structures on the PLGA fabric, preserving cell viability and promoting a nonlinear actin organization. Moreover, the secretion of specific factors involved in angiogenesis, extracellular matrix remodeling, and stem cell homing was enhanced on the PLGA fabric compared to conventional substrates.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Helen Willcockson, Huseyin Ozkan, Jose Valdes-Fernandez, Liubov Arbeeva, Esra Mucahit, Layla Musawwir, Lola B. B. Hooper, Froilan Granero-Molto, Felipe Prosper, Lara Longobardi
Summary: This study investigated the role of Ccr2 in osteoblasts in the progression of post-traumatic osteoarthritis (PTOA) and pain. Early inactivation of Ccr2 in osteoblasts delayed cartilage damage and matrix degeneration, as well as DMM-induced bone thickness. Late deletion had less evident improvements. Our findings suggest that Ccr2 in osteoblasts contributes to PTOA progression and pain.
Article
Hematology
Irene Peris, Silvia Romero-Murillo, Elena Martinez-Balsalobre, Caroline C. Farrington, Elena Arriazu, Nerea Marcotegui, Marta Jimenez-Munoz, Cristina Alburquerque-Prieto, Andrea Torres-Lopez, Vicente Fresquet, Jose A. Martinez-Climent, Maria C. Mateos, Maria L. Cayuela, Goutham Narla, Maria D. Odero, Carmen Vicente
Summary: Venetoclax combination therapies are becoming the standard of care in AML, but their efficacy in older/unfit patients is limited, highlighting the need for more effective therapies. Reactivating protein phosphatase 2A (PP2A) enhances venetoclax activity in AML cells by modulating BCL2 dependency and extracellular signal-regulated kinase signaling. Targeting PP2A increases the efficacy of venetoclax and azacitidine combination therapy in AML.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)